PUNE, India, February 28, 2018 /PRNewswire/ --
According to a new market research report "Immunofluorescence Assay Marketby Product (Reagent, Primary & Secondary Antibody, Kit, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023",
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 165 tables and 34 figures spread through 192 pages and in-depth TOC on "Immunofluorescence Assay Market"
Early buyers will receive 10% customization on this report
"By product, the reagents segment accounted for the largest share of the Immunofluorescence Assay Market in 2017."
On the basis of product, the reagents segment accounted for the largest share of the global Immunofluorescence Assay Market. The large share of this segment is due to growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are driving the growth of the reagents segment.
The cancer segment holds the largest share in 2017
Based on disease, the cancer segment accounted for the largest share of the Immunofluorescence Assay Market. The large share of this segment can be attributed to the fact that the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=255585571
"By type, the indirect immunofluorescence segment held the largest market share of the Immunofluorescence Assay Market in 2017"
Based on type, the immunofluorescence assay is segmented into direct and indirect immunofluorescence. The indirect immunofluorescence assay accounted for the major share of the Immunofluorescence Assay Market. The advantages of indirect immunofluorescence technique such as its sensitivity, flexibility, better amplification of the signal, and lower cost-over direct immunofluorescence is the key factor increasing the adoption of this technique.
"By end user, the pharmaceutical and biotechnology companies segment held the largest market share of the immunofluorescence market in 2017"
Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the Immunofluorescence Assay Market. Factors contributing to its largest share include the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=255585571
"North America dominated the market in 2017"
North America accounted for the largest share of the Immunofluorescence Assay Market in 2017, followed by Europe and Asia Pacific. The rising incidence of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities, and the presence of key players in the region are the major factors responsible for the large share of North American Immunofluorescence Assay Market.
The prominent players in the global Immunofluorescence Assay Market are Thermo Fisher (US), Inova Diagnostics (US), and PerkinElmer (US) held the major share of the Immunofluorescence Assay Market. Other major players operating in this market are Merck Millipore (US), Bio-Rad (US), Abcam (UK), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).
Browse Related Reports
Research Antibodies Market by Product (Antibodies (Primary, Secondary) (Mouse, Rabbit)), Reagents), Technology (Western Blot, Flow Cytometry, Elisa, Immunofluorescence, Immunohistochemistry), Application, & End User - Global Forecast to 2022
Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Salgarkar MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: email@example.com Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets
Subscribe to our Free Newsletters!